Observation on the Localization Process and Standard System Construction of the Bioreagent Industry

Multiple Drivers Accelerating the Localization Process

The upstream raw materials of the bioreagent industry have long relied on imports, especially in fields such as high-end tool enzymes, monoclonal antibodies, and ultra-pure nucleotides. In recent years, influenced by research funding management, supply chain security, and demand for localized services, domestic substitution has become a focal point of the industry. At the policy level, independent innovation and strengthening weak links in the industrial chain are encouraged, but it should be noted that relevant statements do not involve specific policy numbers or wording. Downstream users' demands for cost, lead time, and technical support have also prompted more laboratories and enterprises to try domestic bioreagents.

Localization is not simply price competition. The performance evaluation system of the bioreagent industry is relatively complex. Whether a reagent is suitable depends not only on purity or activity, but also on batch-to-batch stability, documentation completeness, technical service capability, and application scenario compatibility. Therefore, the substitution process typically requires multiple rounds of verification and trial use, and cannot be judged solely based on promotional materials.

Current Status and Challenges of Standards System Development

The standards development of the bioreagent industry is relatively lagging, due to the wide variety of products, diverse methods, and significant differences in application scenarios. Currently, some segmented fields have group standards or industry standards, but coverage remains limited. Enterprise standards play an important role in internal quality control, but indicators and testing methods may differ between enterprises, creating difficulties for downstream comparison.

The formulation of standards needs to balance scientific rigor and operability. For example, the definition of polymerase activity may involve different substrates, buffer systems, and temperature conditions. If not unified, activity units cannot be directly converted between different definitions. For antigens and antibodies, purity testing methods, activity assay methods, and reference materials need to be considered. Promoting standardization in the bioreagent industry helps reduce user verification costs and enhance the market acceptance of domestic raw materials, but standard formulation should fully incorporate opinions from industry, academia, and research institutions to avoid being disconnected from practical realities.

Difficulties in Quality Evaluation and Verification

Evaluating whether domestic bioreagents meet requirements typically requires examination from dimensions including physicochemical properties, functional activity, batch-to-batch consistency, stability, and impurity residues. Physicochemical properties include concentration, purity, pH, conductivity, etc. Functional activity requires designing experiments based on specific applications, such as PCR amplification efficiency, antibody binding capacity, and cell culture support effects. Batch-to-batch consistency requires that key indicators across multiple batches fluctuate within a certain range, which places high demands on production process control capability.

Stability studies often require a long period of time. Enterprises can use accelerated stability testing to predict shelf life, but the correlation between accelerated conditions and real storage conditions needs to be verified. For diagnostic raw materials, comprehensive evaluation may also need to be combined with the performance indicators of diagnostic reagents. As medical-related applications are involved, relevant verification should strictly follow regulatory and quality management system requirements, and unverified data or efficacy claims must not be used.

Industrial Ecosystem Collaboration and User Education

Advancing domestic substitution requires upstream and downstream collaboration. Bioreagent industry suppliers should strengthen communication with end users, providing detailed technical documentation, application notes, and sample testing support. Universities and research institutes can establish objective evaluation mechanisms when using domestic bioreagents, recording user experience and problem feedback. Third-party testing institutions or standardization organizations can organize comparison tests to provide reference data for the industry.

Establish open, traceable raw material and product batch records;

Carry out joint verification projects and publish technical reports or white papers;

Enhance user awareness of domestic reagents through academic conferences and training courses;

Improve after-sales service and respond quickly to user complaints and technical support needs.

User education is equally important. Some laboratories have developed path dependency on imported reagents and believe that switching brands carries high risks. In reality, after systematic verification, some domestic reagents can meet requirements in routine applications. However, it should be noted that differences may exist between different batches and different projects. It is recommended to start with small-scale trial use and gradually expand the scope of use.

Further Thoughts on Standards and Industrial Collaboration

Standardization in the bioreagent industry involves not only product indicators but also packaging, labeling, transportation, and storage. For example, criteria for determining cold chain transportation temperature deviations, stability descriptions after reagent opening, and compatibility of different packaging specifications all require industry-level consensus. The improvement of the standards system helps reduce redundant verification and promote the circulation of domestic reagents between research institutions and manufacturing enterprises.

In addition, digital transformation brings new possibilities to the industry. By establishing reagent performance databases, batch traceability platforms, or user feedback systems, more real-world usage data can be accumulated to drive iteration of products and services.Of course, data sharing needs to balance trade secrets and intellectual property protection, and industry associations or third-party platforms can play a coordinating role in this regard.

Conclusion: Driving Industry Development through Quality and Compliance

The localization of the bioreagent industry is a long-term process that requires sustained investment from companies in technology R&D, quality control, supply chain management, and customer service. In the short term, some high-end products still face technical barriers, but through industry-academia-research collaboration and the development of standards systems, the overall level of the industry is expected to gradually improve. Practitioners should avoid exaggerated claims and insist on winning market recognition through reliable experimental data and consistent product quality. Only localization built on quality and compliance can provide stable, traceable upstream support for scientific research and the healthcare sector.